---
title: "Zanzalintinib (XL092) in Metastatic colorectal cancer: References"
description: "Reference list for the formulary evidence report on Zanzalintinib (XL092) in Metastatic colorectal cancer. 62 cited documents."
canonical: "https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zanzalintinib (XL092) in Metastatic colorectal cancer: References

<a id="references"></a>

## 5 References

1. [American Cancer Society (2026)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70067)
2. [ASCO (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01690)
3. [ASCO (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3630)
4. [Ashouri et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12719898/)
5. [Bhimani et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36063775/)
6. [Blank et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21807639/)
7. [Burge et al. (2026)](https://doi.org/10.1016/j.clcc.2026.04.001)
8. [Cann et al. (2026)](https://profiles.foxchase.org/en/publications/third-line-treatment-decision-making-for-metastatic-colorectal-ca/)
9. [Cayman Chemical (2025)](https://cdn.caymanchem.com/cdn/msds/37749m.pdf)
10. [Centers for Disease Control and Prevention about colorectal cancer page](https://www.cdc.gov/colorectal-cancer/about/index.html)
11. [Centers for Disease Control and Prevention colorectal cancer risk factors page](https://www.cdc.gov/colorectal-cancer/risk-factors/index.html)
12. [Centers for Disease Control and Prevention colorectal cancer symptoms page](https://www.cdc.gov/colorectal-cancer/symptoms/index.html)
13. [Dasari et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37331369/)
14. [Dauki et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3574)
15. [Eng et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31003911/)
16. [EU Clinical Trials Register EudraCT 2021-003243-21](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003243-21/ES)
17. [Exelixis access to investigational therapies policy](https://www.exelixis.com/access-to-investigational-therapies/)
18. [Exelixis clinical trials pipeline](https://www.exelixis.com/clinical-trials-pipeline/)
19. [Exelixis first quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm)
20. [Exelixis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)
21. [Exelixis Form 8-K (2026)](https://ir.exelixis.com/static-files/0eed47bb-77b5-4c6e-ba9b-99a95320f1c0)
22. [Exelixis new drug application acceptance announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-accepted-new-drug-application)
23. [Exelixis second quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm)
24. [Exelixis STELLAR-001 results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-001)
25. [Exelixis STELLAR-303 detailed results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal)
26. [Exelixis STELLAR-303 healthcare professional brochure (2023)](https://www.stellar-studies.com/pdfs/en/Exelixis%20-%20STELLAR-303%20HCP%20Brochure%20VV-MED-01521%20v3.0.pdf)
27. [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint)
28. [Exelixis STELLAR-303 update announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-provides-update-phase-3-stellar-303-trial-evaluating)
29. [FDA (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation)
30. [FDA fruquintinib approval announcement (2023)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer)
31. [FDA nivolumab with ipilimumab approval announcement (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer)
32. [FDA sotorasib with panitumumab approval announcement (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer)
33. [FDA trifluridine and tipiracil with bevacizumab approval announcement (2023)](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-trifluridine-and-tipiracil-bevacizumab-previously-treated-metastatic-colorectal-cancer)
34. [FDA tucatinib with trastuzumab accelerated approval announcement (2023)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer)
35. [Fontana et al. (2025)](https://doi.org/10.1200/jco.2025.43.4_suppl.127)
36. [Garmezy et al. (2025)](https://doi.org/10.1200/jco.2025.43.16_suppl.3101)
37. [Grothey et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23177514/)
38. [Guven et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067816/)
39. [Hecht et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41130252/)
40. [Hsu et al. (2021)](https://aacrjournals.org/mct/article/20/12_Supplement/P248/676008/Abstract-P248-The-tyrosine-kinase-inhibitor-XL092)
41. [Hsu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890135/)
42. [Kawazoe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11328923/)
43. [Kiel et al. (2026)](https://link.springer.com/article/10.1007/s40801-026-00539-9)
44. [Morris et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506310/)
45. [National Cancer Institute Colon Cancer Treatment PDQ](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq)
46. [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zanzalintinib)
47. [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/colorect.html)
48. [Paly et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38976346/)
49. [Patnaik et al. (2021)](https://doi.org/10.1136/jitc-2021-sitc2021.513)
50. [Prager et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37133585/)
51. [Rasschaert and Tejpar (2025)](https://pubmed.ncbi.nlm.nih.gov/41241502/)
52. [Saeed et al. (2024a)](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068442)
53. [Saeed et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11485978/)
54. [Saeed et al. (2025)](https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/LBA30.html.pdf)
55. [Shankaran et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8902339/)
56. [Sharma et al. (2022)](https://www.annalsofoncology.org/article/S0923-7534%2822%2902460-7/fulltext)
57. [Stintzing et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11904580/)
58. [Strohbehn et al. (2026)](https://ascopubs.org/doi/10.1200/OA-25-00112)
59. [Taieb et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39818468/)
60. [Yoshino et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10220270/)
61. [Yoshino et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37236086/)
62. [Yu et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39099411/)

## Related pages
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations.md)
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/executive-summary.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Product information and disease description](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/product-information-and-disease-description.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Clinical evidence](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/clinical-evidence.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economics.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: prevalence by geography](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/prevalence.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/cost-effectiveness-analyses.md)
